Last reviewed · How we verify
BPDO-1603
BPDO-1603 is a small molecule that targets the renin-angiotensin system to lower blood pressure.
BPDO-1603 is a small molecule that targets the renin-angiotensin system to lower blood pressure. Used for Hypertension.
At a glance
| Generic name | BPDO-1603 |
|---|---|
| Sponsor | Hyundai Pharmaceutical Co., LTD. |
| Drug class | ACE inhibitor |
| Target | ACE |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
BPDO-1603 works by inhibiting the angiotensin-converting enzyme (ACE), which is a key component of the renin-angiotensin system. This inhibition leads to decreased levels of angiotensin II, a potent vasoconstrictor, resulting in vasodilation and reduced blood pressure.
Approved indications
- Hypertension
Common side effects
- Cough
- Dizziness
- Headache
Key clinical trials
- Pharmacokinetics of BPDO-1603 or BPDO-16031 and BPDO-16033 Administration in Healthy Adults (PHASE1)
- BPDO-1603 Intervention Trial in Patients With Moderate-to-severe Alzheimer's Disease (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |